While it is fair to say the biotech sector has started to feel the effects of a softening of investor risk appetite, the muted investor appetite for biotech is also perhaps due to the sector entering something of a transitional phase.
The larger commercial-stage companies that led the sector's strong performance over the past few years have matured to resemble their slower-growing pharmaceutical peers. In contrast, investor enthusiasm...
Headed up by Penny Kyle
Ex-Standard life manager Angela Burns
Latest news and analysis
Talking Strategies: The number of companies in Asia with higher payout ratios have grown since the mid-1990s, but some investors remain wary of searching for income in Asia and Japan. In this video, Jupiter's Jason Pidcock and Dan Carter explain why this...